Search :
Sign in or Register  
Welcome Sign in or Don't have an account?Register

Mouse Anti-MGAT2 Recombinant Antibody (6G5) (CBMAB-A5447-LY)


See all MGAT2 antibodies
Online Inquiry

Summary

Host Animal
Mouse
Specificity
Human
Clone
6G5
Antibody Isotype
IgG2a, κ
Application
sELISA, ELISA

Basic Information

Immunogen
MGAT2 (AAH06390, 1 a.a. ~ 447 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human
Antibody Isotype
IgG2a, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
mannosyl (alpha-1,6-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase
Introduction
The product of this gene is a Golgi enzyme catalyzing an essential step in the conversion of oligomannose to complex N-glycans. The enzyme has the typical glycosyltransferase domains: a short N-terminal cytoplasmic domain, a hydrophobic non-cleavable signal-anchor domain, and a C-terminal catalytic domain. Mutations in this gene may lead to carbohydrate-deficient glycoprotein syndrome, type II. The coding region of this gene is intronless. Transcript variants with a spliced 5' UTR may exist, but their biological validity has not been determined. [provided by RefSeq]
Entrez Gene ID
4247
UniProt ID
Q10469
Alternative Names
CDGS2; GLCNACTII; GNT-II; GNT2
Function
Plays an essential role in protein N-glycosylation. Catalyzes the transfer of N-acetylglucosamine (GlcNAc) onto the free terminal mannose moiety in the core structure of the nascent N-linked glycan chain, giving rise to the second branch in complex glycans.
Biological Process
Oligosaccharide biosynthetic process Source: InterPro
Protein N-linked glycosylation Source: GO_Central
Protein N-linked glycosylation via asparagine Source: UniProtKB
Viral protein processing Source: Reactome
Cellular Location
Golgi apparatus membrane
Involvement in disease
Congenital disorder of glycosylation 2A (CDG2A):
A multisystem disorder caused by a defect in glycoprotein biosynthesis and characterized by under-glycosylated serum glycoproteins. Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. The broad spectrum of features reflects the critical role of N-glycoproteins during embryonic development, differentiation, and maintenance of cell functions.
Topology
Cytoplasmic: 1-9
Helical: 10-29
Lumenal: 30-447
More Infomation

Meng, W., Brigance, R., Mignone, J., Negash, L., Zhao, G., Ahmad, S., ... & Devasthale, P. (2023). Discovery of 12 (BMS-986172) as a Highly Potent MGAT2 Inhibitor that Achieved Targeted Efficacious Exposures at a Low Human Dose for the Treatment of Metabolic Disorders. Journal of Medicinal Chemistry, 66(18), 13135-13147.

Moore, F., Wang, W., Zhao, G., Mignone, J., Meng, W., Chu, C. H., ... & Devasthale, P. (2023). Discovery of Novel Pyridinones as MGAT2 Inhibitors for the Treatment of Metabolic Disorders. Bioorganic & Medicinal Chemistry Letters, 129362.

Cheng, D., Zinker, B. A., Luo, Y., Shipkova, P., De Oliveira, C. H., Krishna, G., ... & Gordon, D. A. (2022). MGAT2 inhibitor decreases liver fibrosis and inflammation in murine NASH models and reduces body weight in human adults with obesity. Cell Metabolism, 34(11), 1732-1748.

Kempson, J., Hou, X., Sun, J. H., Wong, M., Pawluczyk, J., Li, J., ... & Mathur, A. (2022). Synthesis Optimization, Scale-Up, and Catalyst Screening Efforts toward the MGAT2 Clinical Candidate, BMS-963272. Organic Process Research & Development, 26(4), 1327-1335.

Turdi, H., Chao, H., Hangeland, J. J., Ahmad, S., Meng, W., Brigance, R., ... & Devasthale, P. (2021). Screening hit to clinical candidate: discovery of BMS-963272, a potent, selective MGAT2 inhibitor for the treatment of metabolic disorders. Journal of Medicinal Chemistry, 64(19), 14773-14792.

Poskanzer, S. A., Schultz, M. J., Turgeon, C. T., Vidal‐Folch, N., Liedtke, K., Oglesbee, D., ... & Lam, C. (2021). Immune dysfunction in MGAT2‐CDG: a clinical report and review of the literature. American Journal of Medical Genetics Part A, 185(1), 213-218.

Mochida, T., Take, K., Maki, T., Nakakariya, M., Adachi, R., Sato, K., ... & Takekawa, S. (2020). Inhibition of MGAT2 modulates fat‐induced gut peptide release and fat intake in normal mice and ameliorates obesity and diabetes in ob/ob mice fed on a high‐fat diet. FEBS Open bio, 10(3), 316-326.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MGAT2 Recombinant Antibody (6G5)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Learn more

Documents

Request bulk or custom quoteOnline Inquiry
Second antibody and isotype control

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Online Inquiry